Buchang Pharmaceuticals has appointed an exclusive distributor in the Philippines for a new drug
August 8, 2025
Source: drugdu
154
On August 7, Buchang Pharmaceutical issued an announcement stating that its controlling subsidiary Luzhou Buchang intends to sign an "Exclusive Supply Agreement" with the Philippine company GOODFELLOW, authorizing the latter to serve as the exclusive agent in the Philippines to complete the registration, related clinical trials, promotion, distribution and sales of the Class I new therapeutic biological drug - Efparepoetin alfa for injection.
This transaction is another breakthrough in the internationalization process of Stepan Pharmaceutical's strategic layout of biopharmaceuticals. While bringing economic benefits to the company, it will also help enhance the company's brand value and have a good driving effect on enhancing the company's core competitiveness.
https://jnzstatic.cs.com.cn/zzb/htmlInfo/101481.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
